Pharmaceutical News and Articles
Clinical Trial Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
SAN DIEGO--(BUSINESS WIRE)--Nov 20, 2009 - Ligand
Pharmaceuticals Incorporated (NASDAQ: LGND) today announced
that data from a preclinical study on its selective androgen
receptor modulator (SARM) LGD-4033 was featured in a poster
presentation at...
Inovio's SynConTM Universal Flu
Vaccines Provide 100% Protection in Ferrets against Death and
Sickness in a Challenge Study with the Pandemic H1N1 Virus
SAN DIEGO--(BUSINESS WIRE)--Nov 20, 2009 - Inovio Biomedical
Corporation (NYSE Amex:INO), a...
Both Live, Attenuated Influenza Vaccine (LAIV) and Trivalent
Inactivated Vaccine (TIV) provide Protection against novel A/H1N1,
especially against severe disease
WASHINGTON, Nov. 19 /PRNewswire/ -- Immunization with either
live attenuated influenza...
Positive Results from Chronic Study with Bayer’s
Rivaroxaban Will be Presented As a Late Breaker at ASH 2009
Endpoints met in EINSTEIN-Extension Trial in the Secondary
Prevention of Recurrent Symptomatic VTE
Berlin, November 19, 2009 -...
Results Underscore Differentiating Profile; Indicate
Significant Market Opportunity for Avanafil
MOUNTAIN VIEW, Calif., Nov. 18 /PRNewswire-FirstCall/ -- VIVUS,
Inc. (NASDAQ:VVUS) today announced positive results
from REVIVE (TA-301), a phase 3...
SAN FRANCISCO, Nov. 18 /PRNewswire/ -- Epiphany Biosciences
announced results from its Phase 2b dose-ranging study of EPB-348
(valomaciclovir) in patients with shingles (herpes zoster)
infection. The study's primary endpoint was non-inferiority...
ENCOURAGING FINAL PHASE IIb RESULTS SEEN WITH LUPUZOR™ IN
SYSTEMIC LUPUS ERYTHEMATOSUS
~ Greatest benefits seen in patients with moderate to severe
Systemic Lupus Erythematosus ~
LONDON, Nov. 19, 2009-ImmuPharma PLC (LSE: IMM) the...
Basel, Switzerland, November 19, 2009 - Basilea Pharmaceutica
Ltd. (SIX:BSLN) presents new research data on its innovative
antitumor drug candidate BAL27862 at the international conference
on Molecular Targets and Cancer Therapeutics in Boston...
STOCKHOLM--(BUSINESS WIRE)--Nov 19, 2009 - Regulatory News:
Medivir (STO:MVIRB):
The Epiphany Biosciences press release reads as follows;
Epiphany Biosciences announced results from its Phase 2b
dose-ranging study of EPB-348 (valomaciclovir)...
Dosing Schedule of Imetelstat Achieves Drug Exposure
Consistent with In Vivo Inhibition of Tumor Growth
MENLO PARK, Calif.--(BUSINESS WIRE)--Nov 19, 2009 - Geron
Corporation (Nasdaq:GERN) today announced the presentation of
interim data from its...
- Broad anti-cancer activity as a single agent and in
combination
- Strong potency against highly resistant cancers
- Superior profile to first generation Hsp90
inhibitors
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 18, 2009 -...
Copper redox reaction key to elesclomol's ability to generate
ROS
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov 18, 2009 - Synta
Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and...
RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Sangamo
BioSciences, Inc. (NASDAQ:SGMO) announced today that data from the
University of Pennsylvania investigator sponsored Phase 1 safety
study of Sangamo's zinc finger nuclease (ZFN) based...
Ticagrelor data presented at the American Heart Association
Scientific Sessions
ORLANDO, Fla., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca
(NYSE:AZN) today announced the results of the
phase II studies, ONSET/OFFSET and RESPOND for...
- In Preclinical Studies, Peregrine's PS-Targeting Antibodies
Including Bavituximab Demonstrated Broad Spectrum Binding to
Viruses and Virally Infected Cells Representing Three Viral
Hemorrhagic Fever (VHF) Families - - Preclinical Efficacy...
BOSTON--(BUSINESS WIRE)--Nov 18, 2009 - Exelixis, Inc.
(Nasdaq:EXEL) today reported interim data from an ongoing phase 1
dose-escalation trial of XL147 (SAR245408) in combination with the
EGFR inhibitor erlotinib in patients with advanced solid...
Retrospective Analysis of Almost 30,000 Patients Shows No
Significant Difference in Risk of Heart Attack or Stroke with
Monotherapy Compared With Combination Therapy
IRVINE, Calif.--(BUSINESS WIRE)--Nov 18, 2009 - Prescription
Solutions, a leading...
Data to be presented at 12th Congress of the European Society
for Sexual Medicine, November 15th to 18th, Lyon
SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A
Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced
today that it has...
Threshold Pharmaceuticals Presents Interim Prostate Cancer Data
From Early Stage Trials of TH-302
REDWOOD CITY, Calif., Nov. 18, 2009 (GLOBE NEWSWIRE) --
Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced
clinical trial results related to...
VT-111 significantly reduces key cardiac enzymes at multiple
time points after stent placement; Data presented at American Heart
Association 2009 Scientific Sessions
LONDON, ON, Nov. 18 /PRNewswire/ -- Viron Therapeutics Inc., a
biotechnology...
More...
